Bella Mehta
Tweet
Phase 2, OA trial. Abstract 1927 at #ACR26 suggests that selecting patients with elevated hsCRP and MRI synovitis may help identify an inflammatory OA phenotype responsive to NLRP3 inhibition. A compelling direction, but larger confirmatory trials are needed. @rheumnow https://t.co/DJKCm8CnS4
